Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1616
    -0.0067 (-0.58%)
     

  • GBP/USD

    1.2373
    -0.0066 (-0.53%)
     

  • Bitcoin GBP

    51,994.21
    +1,033.93 (+2.03%)
     

  • CMC Crypto 200

    1,384.21
    +71.59 (+5.46%)
     

  • S&P 500

    4,961.79
    -49.33 (-0.98%)
     

  • DOW

    37,892.09
    +116.71 (+0.31%)
     

  • CRUDE OIL

    83.14
    +0.41 (+0.50%)
     

  • GOLD FUTURES

    2,409.70
    +11.70 (+0.49%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

BUZZ-Indivior: Shares plummet on U.S. court patent ruling

Reuters - UK Focus

** Indivior (Frankfurt: 2IVA.F - news) 's shares down 22 pct after U.S. Court finds would-be generic competitor Alvogen had not infringed three of its patents

** Co says will fight the ruling, believes it has grounds to appeal

** INDV shares bottom of FTSE Mid Cap; fall as much as 23.5 pct

** "Unless the generic maker launches at risk, these patents would need to be litigated first, a process which could take two years," Morgan Stanley (Xetra: 885836 - news) believes

** Jefferies says impact of ruling is less significant given that Dr Reddy's Labs is still the most likely to launch a generic first

** "Any market over-reaction would be a good buying opportunity," Jefferies says